[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [Benef](https://github.com/mm80843/T3.5/tree/main/docs/Benef/index.md) >> Individual ID:PBN__Benef_1119 

# __Reduction in airborne SARS-CoV-2__

## Name of the Benefit

Air filtration devices effectively remove airborne SARS-CoV-2, reducing the risk of hospital-acquired infections.

## Description of actual returns pertaining to this benefit

* [Private investors would benefit from investing in air filtration devices as it would improve patient safety and reduce healthcare costs associated with hospital-acquired infections.](https://github.com/mm80843/T3.5/blob/main/docs/BenefReturn/PBN__BenefReturn_1251.md)

## Articles mentionning this Benefit

* [The removal of airborne SARS-CoV-2 and other microbial bioaerosols by air filtration on COVID-19 surge units](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_232.md)

## Stakeholders benefitting from this Benefit

* [healthcare workers](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_68.md)
* [patients](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_31.md)

## Risks which can benefit from this action

* [Air filtration and UV light sterilisation](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1130.md)

